Patents by Inventor Joshua Ryan Dahlke
Joshua Ryan Dahlke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11964989Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 20, 2022Date of Patent: April 23, 2024Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
-
Publication number: 20240002384Abstract: The invention relates to a method of treating a MEK-associated tumor by administering to a subject in need thereof a therapeutically effective amount of a solid form 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.Type: ApplicationFiled: September 18, 2023Publication date: January 4, 2024Applicant: Pfizer Inc.Inventors: Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS, Jennifer Lynn FULTON
-
Publication number: 20230357277Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.Type: ApplicationFiled: September 21, 2021Publication date: November 9, 2023Inventors: Xiaolun Wang, Matthew Arnold Marx, Shelley Allen, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Michael Christopher Hilton, Dean Russell Kahn, Macedonio Junior Mejia, Phong Nguyen, Spencer Pajk, Martha E. Rodriguez, Pavel Yu Savechenkov, Tony Pisal Tang
-
Patent number: 11802127Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.Type: GrantFiled: March 30, 2022Date of Patent: October 31, 2023Assignee: Pfizer Inc.Inventors: Shelley Allen, Patrick Michael Doerner Barbour, James Francis Blake, Mark Laurence Boys, Joshua Ryan Dahlke, Alex Andrew Kellum, David Austin Moreno, Jacob Matthew O'Leary, Li Ren
-
Publication number: 20230339976Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.Type: ApplicationFiled: August 3, 2021Publication date: October 26, 2023Inventors: Xiaolun Wang, Matthew Arnold Marx, John David Lawson, Shelley Allen, Patrick Michael Barbour, James Francis Blake, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Sherif Hosam Hassanien, Michael Christopher Hilton, Macedonio Junior Mejia, Jacob Matthew O’Leary, Tony Pisal Tang
-
Publication number: 20230279025Abstract: The present invention relates to compounds that inhibit KRas G12D, In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.Type: ApplicationFiled: February 25, 2021Publication date: September 7, 2023Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James Francis Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
-
Patent number: 11691973Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.Type: GrantFiled: December 1, 2022Date of Patent: July 4, 2023Assignee: Pfizer Inc.Inventors: Shelley Allen, Patrick Michael Doerner Barbour, James Francis Blake, Sydney Taylor Blanche, Mark Laurence Boys, Wesley Dewitt Clark, Connor James Cowdrey, Joshua Ryan Dahlke, Alex Andrew Kellum, Ellen Margaret Knapp, David Austin Moreno, Jacob Matthew O'Leary, Li Ren, Faith Elizabeth Witkos, Jennifer Lynn Fulton
-
Publication number: 20230120188Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.Type: ApplicationFiled: December 1, 2022Publication date: April 20, 2023Applicant: Pfizer Inc.Inventors: Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS
-
Publication number: 20230077225Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.Type: ApplicationFiled: July 20, 2022Publication date: March 9, 2023Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
-
Publication number: 20220324861Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.Type: ApplicationFiled: March 30, 2022Publication date: October 13, 2022Applicant: Pfizer Inc.Inventors: Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS
-
Patent number: 11453683Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 27, 2020Date of Patent: September 27, 2022Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton